Sara Rapic1, Christel Vangestel1,2, Filipe Elvas1,2, Jeroen Verhaeghe1, Tim Van den Wyngaert1,2, Leonie Wyffels1,2, Patrick Pauwels3,4, Steven Staelens1, Sigrid Stroobants5,6. 1. Molecular Imaging Center Antwerp (MICA), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium. 2. Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium. 3. Center for Oncological Research (CORE), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium. 4. Department of Pathology, Antwerp University Hospital, Edegem, Belgium. 5. Molecular Imaging Center Antwerp (MICA), Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium. Sigrid.Stroobants@uza.be. 6. Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium. Sigrid.Stroobants@uza.be.
Abstract
PURPOSE: The substrate-based positron emission tomography (PET) tracer [18F]CP18 is capable of detecting the activity of caspase-3/7, two key executioner proteases in the apoptosis pathway, through selective cleavage of the ligand by the activated proteases and subsequent accumulation in apoptotic cells. Using an in vitro and in vivo model of colorectal cancer (CRC), we investigated whether [18F]CP18 tracer accumulation provides a measure for apoptosis and reliably reflects early treatment response to chemotherapeutics. PROCEDURES: [18F]CP18 cell uptake was assessed in treated Colo205 cells (saline, 5-fluorouracil (5-FU), irinotecan or their combination) and correlated with caspase-3/7 activity. [18F]CP18 imaging was performed in Colo205 xenografts, starting with a baseline μPET/micro X-ray computed tomography (μCT) scan, followed by a 3-day treatment with saline (n = 5), 5-FU (low sensitivity, n = 4), irinotecan (high sensitivity, n = 5), or a combination of both (n = 7). The study was concluded with a second [18F]CP18 scan, 24 h after final treatment administration, followed by tumor removal for gamma counting (%ID/g) and for cleaved caspase-3 immunohistochemistry (apoptotic index/necrosis). Tumors were delineated on μCT images and, using the obtained volumes of interest, average percentage injected dose per cubic centimeter (%ID/cm3) was calculated from every μPET image. RESULTS: In vitro, [18F]CP18 cell uptake was positively correlated with caspase-3/7 activity (r = 0.59, p = 0.003). A drug-dependent increase in [18F]CP18 tumor uptake compared to baseline was observed in animals treated with 5-FU (+14 ± 25 %), irinotecan (+56 ± 54 %), and their combination (+158 ± 69 %, p = 0.002). %ID/cm3 showed a positive relationship with both %ID/g (r = 0.83, p < 0.0001) and the apoptotic index (r = 0.60, p = 0.004), but not with tumor necrosis (r = 0.22, p = 0.36). CONCLUSION: Both our in vitro and in vivo findings have shown the ability of [18F]CP18-PET to visualize therapy-induced cancer cell apoptosis and possibly serve as a biomarker for early therapy response.
PURPOSE: The substrate-based positron emission tomography (PET) tracer [18F]CP18 is capable of detecting the activity of caspase-3/7, two key executioner proteases in the apoptosis pathway, through selective cleavage of the ligand by the activated proteases and subsequent accumulation in apoptotic cells. Using an in vitro and in vivo model of colorectal cancer (CRC), we investigated whether [18F]CP18 tracer accumulation provides a measure for apoptosis and reliably reflects early treatment response to chemotherapeutics. PROCEDURES: [18F]CP18 cell uptake was assessed in treated Colo205 cells (saline, 5-fluorouracil (5-FU), irinotecan or their combination) and correlated with caspase-3/7 activity. [18F]CP18 imaging was performed in Colo205 xenografts, starting with a baseline μPET/micro X-ray computed tomography (μCT) scan, followed by a 3-day treatment with saline (n = 5), 5-FU (low sensitivity, n = 4), irinotecan (high sensitivity, n = 5), or a combination of both (n = 7). The study was concluded with a second [18F]CP18 scan, 24 h after final treatment administration, followed by tumor removal for gamma counting (%ID/g) and for cleaved caspase-3 immunohistochemistry (apoptotic index/necrosis). Tumors were delineated on μCT images and, using the obtained volumes of interest, average percentage injected dose per cubic centimeter (%ID/cm3) was calculated from every μPET image. RESULTS: In vitro, [18F]CP18 cell uptake was positively correlated with caspase-3/7 activity (r = 0.59, p = 0.003). A drug-dependent increase in [18F]CP18 tumor uptake compared to baseline was observed in animals treated with 5-FU (+14 ± 25 %), irinotecan (+56 ± 54 %), and their combination (+158 ± 69 %, p = 0.002). %ID/cm3 showed a positive relationship with both %ID/g (r = 0.83, p < 0.0001) and the apoptotic index (r = 0.60, p = 0.004), but not with tumor necrosis (r = 0.22, p = 0.36). CONCLUSION: Both our in vitro and in vivo findings have shown the ability of [18F]CP18-PET to visualize therapy-induced cancer cell apoptosis and possibly serve as a biomarker for early therapy response.
Authors: Christel Vangestel; Marc Peeters; Ruth Oltenfreiter; Yves D'Asseler; Steven Staelens; Magali Van Steenkiste; Jan Philippé; Dennis Kusters; Chris Reutelingsperger; Nancy Van Damme; Christophe Van de Wiele Journal: Nucl Med Biol Date: 2010-09-20 Impact factor: 2.408
Authors: Helen Su; Gang Chen; Umesh Gangadharmath; Luis F Gomez; Qianwa Liang; Fanrong Mu; Vani P Mocharla; A Katrin Szardenings; Joseph C Walsh; Chun-Fang Xia; Chul Yu; Hartmuth C Kolb Journal: Mol Imaging Biol Date: 2013-12 Impact factor: 3.488
Authors: Chun-Fang Xia; Gang Chen; Umesh Gangadharmath; Luis F Gomez; Qianwa Liang; Fanrong Mu; Vani P Mocharla; Helen Su; A Katrin Szardenings; Joseph C Walsh; Tieming Zhao; Hartmuth C Kolb Journal: Mol Imaging Biol Date: 2013-12 Impact factor: 3.488
Authors: Chris P M Reutelingsperger; Ewald Dumont; Paul W Thimister; Hugo van Genderen; Heidi Kenis; Stefan van de Eijnde; Guido Heidendal; Leo Hofstra Journal: J Immunol Methods Date: 2002-07-01 Impact factor: 2.303
Authors: Quang-Dé Nguyen; Graham Smith; Matthias Glaser; Meg Perumal; Erik Arstad; Eric O Aboagye Journal: Proc Natl Acad Sci U S A Date: 2009-09-03 Impact factor: 11.205
Authors: Mohan Doss; Hartmuth C Kolb; Joseph C Walsh; Vani Mocharla; Hong Fan; Ashok Chaudhary; Zhihong Zhu; R Katherine Alpaugh; Miriam N Lango; Jian Q Yu Journal: J Nucl Med Date: 2013-10-17 Impact factor: 10.057
Authors: Quang-Dé Nguyen; Ioannis Lavdas; James Gubbins; Graham Smith; Robin Fortt; Laurence S Carroll; Martin A Graham; Eric O Aboagye Journal: Clin Cancer Res Date: 2013-05-31 Impact factor: 12.531
Authors: Anna A Rybczynska; Hendrikus H Boersma; Steven de Jong; Jourik A Gietema; Walter Noordzij; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde Journal: Med Res Rev Date: 2018-03-12 Impact factor: 12.944
Authors: Valeriy G Ostapchenko; Jonatan Snir; Mojmir Suchy; Jue Fan; M Rebecca Cobb; Blaine A Chronik; Michael Kovacs; Vania F Prado; Robert H E Hudson; Stephen H Pasternak; Marco A M Prado; Robert Bartha Journal: Contrast Media Mol Imaging Date: 2019-01-14 Impact factor: 3.161
Authors: Christophe Van de Wiele; Sezgin Ustmert; Bart De Spiegeleer; Pieter-Jan De Jonghe; Mike Sathekge; Maes Alex Journal: Int J Mol Sci Date: 2021-03-09 Impact factor: 5.923